[

Metastatic Monitoring PET/CT Prostate cancer [68Ga]Ga-PSMA-11

Journal

EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946

Informations de publication

Date de publication:
29 Aug 2019
Historique:
received: 13 06 2019
accepted: 20 08 2019
entrez: 31 8 2019
pubmed: 31 8 2019
medline: 31 8 2019
Statut: epublish

Résumé

The aim of the current study was to assess whether and to what extent monitoring response to treatment using prostate-specific membrane antigen (PSMA)-based positron-emitting tomography/computerized tomography (PET/CT) studies contribute clinically relevant data to routine clinical follow-up during treatment of patients with metastatic prostate cancer (PCa). Fifty-two patients with metastatic PCa who underwent [ Results of this retrospective analysis showed that biochemical responses to treatment and [

Sections du résumé

BACKGROUND BACKGROUND
The aim of the current study was to assess whether and to what extent monitoring response to treatment using prostate-specific membrane antigen (PSMA)-based positron-emitting tomography/computerized tomography (PET/CT) studies contribute clinically relevant data to routine clinical follow-up during treatment of patients with metastatic prostate cancer (PCa).
RESULTS RESULTS
Fifty-two patients with metastatic PCa who underwent [
CONCLUSIONS CONCLUSIONS
Results of this retrospective analysis showed that biochemical responses to treatment and [

Identifiants

pubmed: 31468235
doi: 10.1186/s13550-019-0554-1
pii: 10.1186/s13550-019-0554-1
pmc: PMC6715755
doi:

Types de publication

Journal Article

Langues

eng

Pagination

84

Références

Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Oncotarget. 2014 Dec 15;5(23):12448-58
pubmed: 25504434
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):84-91
pubmed: 26323576
Future Oncol. 2016 Feb;12(3):333-42
pubmed: 26768648
Cancer Imaging. 2016 Jun 08;16(1):14
pubmed: 27277843
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268
pubmed: 28497198
J Nucl Med. 2017 Dec;58(12):1962-1968
pubmed: 28522740
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):78-83
pubmed: 28540419
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2117-2136
pubmed: 28765998
Strahlenther Onkol. 2018 Apr;194(4):318-324
pubmed: 29181556
Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):602-612
pubmed: 29185010
Radiographics. 2018 Jan-Feb;38(1):200-217
pubmed: 29320333
Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1862-1872
pubmed: 29725716
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2035-2044
pubmed: 29922948
Eur J Nucl Med Mol Imaging. 2019 Apr;46(4):908-920
pubmed: 30635755
Nuklearmedizin. 2019 May 13;:null
pubmed: 31083752

Auteurs

Jonathan Kuten (J)

Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, 6 Weizmann St, 6423906, Tel-Aviv, Israel.

David Sarid (D)

Department of Oncology (Uro-Oncology section), Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, 6 Weizmann St, 6423906, Tel-Aviv, Israel.

Ofer Yossepowitch (O)

Department of Urology, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, 6 Weizmann St, 6423906, Tel-Aviv, Israel.

Nicola J Mabjeesh (NJ)

Department of Urology, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, 6 Weizmann St, 6423906, Tel-Aviv, Israel.

Einat Even-Sapir (E)

Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, 6 Weizmann St, 6423906, Tel-Aviv, Israel. evensap@tlvmc.gov.il.

Classifications MeSH